Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment: Systematic review and retrospective cohort analysis

Research output: Contribution to journalReviewResearchpeer-review

Standard

Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment : Systematic review and retrospective cohort analysis. / Davies, Bethan; Turner, Katy M. E.; Leung, Stella; Yu, B. Nancy; Frølund, Maria; Benfield, Thomas; Blanchard, James; Westh, Henrik T.; Ward, Helen.

In: PloS one, Vol. 12, No. 2, e0171551, 2017.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Davies, B, Turner, KME, Leung, S, Yu, BN, Frølund, M, Benfield, T, Blanchard, J, Westh, HT & Ward, H 2017, 'Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment: Systematic review and retrospective cohort analysis', PloS one, vol. 12, no. 2, e0171551. https://doi.org/10.1371/journal.pone.0171551

APA

Davies, B., Turner, K. M. E., Leung, S., Yu, B. N., Frølund, M., Benfield, T., ... Ward, H. (2017). Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment: Systematic review and retrospective cohort analysis. PloS one, 12(2), [e0171551]. https://doi.org/10.1371/journal.pone.0171551

Vancouver

Davies B, Turner KME, Leung S, Yu BN, Frølund M, Benfield T et al. Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment: Systematic review and retrospective cohort analysis. PloS one. 2017;12(2). e0171551. https://doi.org/10.1371/journal.pone.0171551

Author

Davies, Bethan ; Turner, Katy M. E. ; Leung, Stella ; Yu, B. Nancy ; Frølund, Maria ; Benfield, Thomas ; Blanchard, James ; Westh, Henrik T. ; Ward, Helen. / Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment : Systematic review and retrospective cohort analysis. In: PloS one. 2017 ; Vol. 12, No. 2.

Bibtex

@article{b9f63a6d38f941efaf9e853b4292859e,
title = "Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment: Systematic review and retrospective cohort analysis",
abstract = "BACKGROUND: The impact of Chlamydia trachomatis (chlamydia) control on the incidence of pelvic inflammatory disease (PID) is theoretically limited by the proportion of PID caused by chlamydia. We estimate the population excess fraction (PEF) of treated chlamydia infection on PID at 12-months in settings with widespread chlamydia control (testing and treatment) and compare this to the estimated PEF of untreated chlamydia.METHODS: We used two large retrospective population-based cohorts of women of reproductive age from settings with widespread chlamydia control to calculate the PEF of treated chlamydia on PID at 12-months. We undertook a systematic review to identify further studies that reported the risk of PID in women who were tested for chlamydia (infected and uninfected). We used the same method to calculate the PEF in eligible studies then compared all estimates of PEF.RESULTS: The systematic review identified a single study, a randomised controlled trial of chlamydia screening (POPI-RCT). In the presence of testing and treatment <10{\%} of PID at 12-months was attributable to treated (baseline) chlamydia infections (Manitoba: 8.86{\%}(95{\%}CI 7.15-10.75); Denmark: 3.84{\%}(3.26-4.45); screened-arm POPI-RCT: 0.99{\%}(0.00-29.06)). In the absence of active chlamydia treatment 26.44{\%}(11.57-46.32) of PID at 12-months was attributable to untreated (baseline) chlamydia infections (deferred-arm POPI-RCT). The PEFs suggest that eradicating baseline chlamydia infections could prevent 484 cases of PID at 12-months per 100,000 women in the untreated setting and 13-184 cases of PID per 100,000 tested women in the presence of testing and treatment.CONCLUSION: Testing and treating chlamydia reduced the PEF of chlamydia on PID by 65{\%} compared to the untreated setting. But in the presence of testing and treatment over 90{\%} of PID could not be attributed to a baseline chlamydia infection. More information is needed about the aetiology of PID to develop effective strategies for improving the reproductive health of women.",
keywords = "Chlamydia Infections/complications, Chlamydia trachomatis/isolation & purification, Clinical Trials as Topic, Female, Humans, Pelvic Inflammatory Disease/complications, Prevalence, Retrospective Studies, Risk",
author = "Bethan Davies and Turner, {Katy M. E.} and Stella Leung and Yu, {B. Nancy} and Maria Fr{\o}lund and Thomas Benfield and James Blanchard and Westh, {Henrik T.} and Helen Ward",
year = "2017",
doi = "10.1371/journal.pone.0171551",
language = "English",
volume = "12",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

RIS

TY - JOUR

T1 - Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment

T2 - Systematic review and retrospective cohort analysis

AU - Davies, Bethan

AU - Turner, Katy M. E.

AU - Leung, Stella

AU - Yu, B. Nancy

AU - Frølund, Maria

AU - Benfield, Thomas

AU - Blanchard, James

AU - Westh, Henrik T.

AU - Ward, Helen

PY - 2017

Y1 - 2017

N2 - BACKGROUND: The impact of Chlamydia trachomatis (chlamydia) control on the incidence of pelvic inflammatory disease (PID) is theoretically limited by the proportion of PID caused by chlamydia. We estimate the population excess fraction (PEF) of treated chlamydia infection on PID at 12-months in settings with widespread chlamydia control (testing and treatment) and compare this to the estimated PEF of untreated chlamydia.METHODS: We used two large retrospective population-based cohorts of women of reproductive age from settings with widespread chlamydia control to calculate the PEF of treated chlamydia on PID at 12-months. We undertook a systematic review to identify further studies that reported the risk of PID in women who were tested for chlamydia (infected and uninfected). We used the same method to calculate the PEF in eligible studies then compared all estimates of PEF.RESULTS: The systematic review identified a single study, a randomised controlled trial of chlamydia screening (POPI-RCT). In the presence of testing and treatment <10% of PID at 12-months was attributable to treated (baseline) chlamydia infections (Manitoba: 8.86%(95%CI 7.15-10.75); Denmark: 3.84%(3.26-4.45); screened-arm POPI-RCT: 0.99%(0.00-29.06)). In the absence of active chlamydia treatment 26.44%(11.57-46.32) of PID at 12-months was attributable to untreated (baseline) chlamydia infections (deferred-arm POPI-RCT). The PEFs suggest that eradicating baseline chlamydia infections could prevent 484 cases of PID at 12-months per 100,000 women in the untreated setting and 13-184 cases of PID per 100,000 tested women in the presence of testing and treatment.CONCLUSION: Testing and treating chlamydia reduced the PEF of chlamydia on PID by 65% compared to the untreated setting. But in the presence of testing and treatment over 90% of PID could not be attributed to a baseline chlamydia infection. More information is needed about the aetiology of PID to develop effective strategies for improving the reproductive health of women.

AB - BACKGROUND: The impact of Chlamydia trachomatis (chlamydia) control on the incidence of pelvic inflammatory disease (PID) is theoretically limited by the proportion of PID caused by chlamydia. We estimate the population excess fraction (PEF) of treated chlamydia infection on PID at 12-months in settings with widespread chlamydia control (testing and treatment) and compare this to the estimated PEF of untreated chlamydia.METHODS: We used two large retrospective population-based cohorts of women of reproductive age from settings with widespread chlamydia control to calculate the PEF of treated chlamydia on PID at 12-months. We undertook a systematic review to identify further studies that reported the risk of PID in women who were tested for chlamydia (infected and uninfected). We used the same method to calculate the PEF in eligible studies then compared all estimates of PEF.RESULTS: The systematic review identified a single study, a randomised controlled trial of chlamydia screening (POPI-RCT). In the presence of testing and treatment <10% of PID at 12-months was attributable to treated (baseline) chlamydia infections (Manitoba: 8.86%(95%CI 7.15-10.75); Denmark: 3.84%(3.26-4.45); screened-arm POPI-RCT: 0.99%(0.00-29.06)). In the absence of active chlamydia treatment 26.44%(11.57-46.32) of PID at 12-months was attributable to untreated (baseline) chlamydia infections (deferred-arm POPI-RCT). The PEFs suggest that eradicating baseline chlamydia infections could prevent 484 cases of PID at 12-months per 100,000 women in the untreated setting and 13-184 cases of PID per 100,000 tested women in the presence of testing and treatment.CONCLUSION: Testing and treating chlamydia reduced the PEF of chlamydia on PID by 65% compared to the untreated setting. But in the presence of testing and treatment over 90% of PID could not be attributed to a baseline chlamydia infection. More information is needed about the aetiology of PID to develop effective strategies for improving the reproductive health of women.

KW - Chlamydia Infections/complications

KW - Chlamydia trachomatis/isolation & purification

KW - Clinical Trials as Topic

KW - Female

KW - Humans

KW - Pelvic Inflammatory Disease/complications

KW - Prevalence

KW - Retrospective Studies

KW - Risk

U2 - 10.1371/journal.pone.0171551

DO - 10.1371/journal.pone.0171551

M3 - Review

C2 - 28199392

VL - 12

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 2

M1 - e0171551

ER -

ID: 193664473